FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2942752034> ?p ?o ?g. }

• W2942752034 endingPage "9575" @default.
• W2942752034 startingPage "9567" @default.
• W2942752034 abstract "Inhibitors of methionine aminopeptidase 2 (MetAP2) have been shown to reduce body weight in obese mice and humans. The target tissue and cellular mechanism of MetAP2 inhibitors, however, have not been extensively examined. Using compounds with diverse chemical scaffolds, we showed that MetAP2 inhibition decreases body weight and fat mass and increases lean mass in the obese mice but not in the lean mice. Obesity is associated with catecholamine resistance and blunted β-adrenergic receptor signaling activities, which could dampen lipolysis and energy expenditure resulting in weight gain. In the current study, we examined effect of MetAP2 inhibition on brown adipose tissue and brown adipocytes. Norepinephrine increases energy expenditure in brown adipose tissue by providing fatty acid substrate through lipolysis and by increasing expression of uncoupled protein-1 (UCP1). Metabolomic analysis shows that in response to MetAP2 inhibitor treatment, fatty acid metabolites in brown adipose tissue increase transiently and subsequently decrease to basal or below basal levels, suggesting an effect on fatty acid metabolism in this tissue. Treatment of brown adipocytes with MetAP2 inhibitors enhances norepinephrine-induced lipolysis and energy expenditure, and prolongs the activity of norepinephrine to increase ucp1 gene expression and energy expenditure in norepinephrine-desensitized brown adipocytes. In summary, we showed that the anti-obesity activity of MetAP2 inhibitors can be mediated, at least in part, through direct action on brown adipocytes by enhancing β-adrenergic–signaling–stimulated activities. Inhibitors of methionine aminopeptidase 2 (MetAP2) have been shown to reduce body weight in obese mice and humans. The target tissue and cellular mechanism of MetAP2 inhibitors, however, have not been extensively examined. Using compounds with diverse chemical scaffolds, we showed that MetAP2 inhibition decreases body weight and fat mass and increases lean mass in the obese mice but not in the lean mice. Obesity is associated with catecholamine resistance and blunted β-adrenergic receptor signaling activities, which could dampen lipolysis and energy expenditure resulting in weight gain. In the current study, we examined effect of MetAP2 inhibition on brown adipose tissue and brown adipocytes. Norepinephrine increases energy expenditure in brown adipose tissue by providing fatty acid substrate through lipolysis and by increasing expression of uncoupled protein-1 (UCP1). Metabolomic analysis shows that in response to MetAP2 inhibitor treatment, fatty acid metabolites in brown adipose tissue increase transiently and subsequently decrease to basal or below basal levels, suggesting an effect on fatty acid metabolism in this tissue. Treatment of brown adipocytes with MetAP2 inhibitors enhances norepinephrine-induced lipolysis and energy expenditure, and prolongs the activity of norepinephrine to increase ucp1 gene expression and energy expenditure in norepinephrine-desensitized brown adipocytes. In summary, we showed that the anti-obesity activity of MetAP2 inhibitors can be mediated, at least in part, through direct action on brown adipocytes by enhancing β-adrenergic–signaling–stimulated activities." @default.
• W2942752034 created "2019-05-09" @default.
• W2942752034 creator A5004599775 @default.
• W2942752034 creator A5007416633 @default.
• W2942752034 creator A5019352600 @default.
• W2942752034 creator A5027500883 @default.
• W2942752034 creator A5070436482 @default.
• W2942752034 creator A5074423360 @default.
• W2942752034 creator A5075654794 @default.
• W2942752034 creator A5075671498 @default.
• W2942752034 creator A5081195818 @default.
• W2942752034 date "2019-06-01" @default.
• W2942752034 modified "2023-10-14" @default.
• W2942752034 title "MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes" @default.
• W2942752034 cites W1911089380 @default.
• W2942752034 cites W1991749464 @default.
• W2942752034 cites W1999239339 @default.
• W2942752034 cites W2006745349 @default.
• W2942752034 cites W2012034410 @default.
• W2942752034 cites W2014671368 @default.
• W2942752034 cites W2024611690 @default.
• W2942752034 cites W2028904367 @default.
• W2942752034 cites W2032830244 @default.
• W2942752034 cites W2040087293 @default.
• W2942752034 cites W2080217697 @default.
• W2942752034 cites W2089319338 @default.
• W2942752034 cites W2098387318 @default.
• W2942752034 cites W2114756704 @default.
• W2942752034 cites W2121051938 @default.
• W2942752034 cites W2145668345 @default.
• W2942752034 cites W2152788276 @default.
• W2942752034 cites W2163400298 @default.
• W2942752034 cites W2165958384 @default.
• W2942752034 cites W2284080609 @default.
• W2942752034 cites W2346592443 @default.
• W2942752034 cites W2510840747 @default.
• W2942752034 cites W2548393767 @default.
• W2942752034 cites W2593570932 @default.
• W2942752034 cites W2618318751 @default.
• W2942752034 doi "https://doi.org/10.1074/jbc.ra118.007302" @default.
• W2942752034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6579473" @default.
• W2942752034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31048375" @default.
• W2942752034 hasPublicationYear "2019" @default.
• W2942752034 type Work @default.
• W2942752034 sameAs 2942752034 @default.
• W2942752034 citedByCount "7" @default.
• W2942752034 countsByYear W29427520342019 @default.
• W2942752034 countsByYear W29427520342020 @default.
• W2942752034 countsByYear W29427520342021 @default.
• W2942752034 countsByYear W29427520342023 @default.
• W2942752034 crossrefType "journal-article" @default.
• W2942752034 hasAuthorship W2942752034A5004599775 @default.
• W2942752034 hasAuthorship W2942752034A5007416633 @default.
• W2942752034 hasAuthorship W2942752034A5019352600 @default.
• W2942752034 hasAuthorship W2942752034A5027500883 @default.
• W2942752034 hasAuthorship W2942752034A5070436482 @default.
• W2942752034 hasAuthorship W2942752034A5074423360 @default.
• W2942752034 hasAuthorship W2942752034A5075654794 @default.
• W2942752034 hasAuthorship W2942752034A5075671498 @default.
• W2942752034 hasAuthorship W2942752034A5081195818 @default.
• W2942752034 hasBestOaLocation W29427520341 @default.
• W2942752034 hasConcept C126322002 @default.
• W2942752034 hasConcept C134018914 @default.
• W2942752034 hasConcept C140985366 @default.
• W2942752034 hasConcept C151279926 @default.
• W2942752034 hasConcept C151955695 @default.
• W2942752034 hasConcept C171089720 @default.
• W2942752034 hasConcept C185592680 @default.
• W2942752034 hasConcept C2780642333 @default.
• W2942752034 hasConcept C543025807 @default.
• W2942752034 hasConcept C55493867 @default.
• W2942752034 hasConcept C62231903 @default.
• W2942752034 hasConcept C71924100 @default.
• W2942752034 hasConcept C81979416 @default.
• W2942752034 hasConcept C86803240 @default.
• W2942752034 hasConcept C96942376 @default.
• W2942752034 hasConceptScore W2942752034C126322002 @default.
• W2942752034 hasConceptScore W2942752034C134018914 @default.
• W2942752034 hasConceptScore W2942752034C140985366 @default.
• W2942752034 hasConceptScore W2942752034C151279926 @default.
• W2942752034 hasConceptScore W2942752034C151955695 @default.
• W2942752034 hasConceptScore W2942752034C171089720 @default.
• W2942752034 hasConceptScore W2942752034C185592680 @default.
• W2942752034 hasConceptScore W2942752034C2780642333 @default.
• W2942752034 hasConceptScore W2942752034C543025807 @default.
• W2942752034 hasConceptScore W2942752034C55493867 @default.
• W2942752034 hasConceptScore W2942752034C62231903 @default.
• W2942752034 hasConceptScore W2942752034C71924100 @default.
• W2942752034 hasConceptScore W2942752034C81979416 @default.
• W2942752034 hasConceptScore W2942752034C86803240 @default.
• W2942752034 hasConceptScore W2942752034C96942376 @default.
• W2942752034 hasIssue "24" @default.
• W2942752034 hasLocation W29427520341 @default.
• W2942752034 hasLocation W29427520342 @default.
• W2942752034 hasLocation W29427520343 @default.
• W2942752034 hasOpenAccess W2942752034 @default.
• W2942752034 hasPrimaryLocation W29427520341 @default.
• W2942752034 hasRelatedWork W1592119877 @default.

• next